JPWO2023151575A5 - - Google Patents
Info
- Publication number
- JPWO2023151575A5 JPWO2023151575A5 JP2024547308A JP2024547308A JPWO2023151575A5 JP WO2023151575 A5 JPWO2023151575 A5 JP WO2023151575A5 JP 2024547308 A JP2024547308 A JP 2024547308A JP 2024547308 A JP2024547308 A JP 2024547308A JP WO2023151575 A5 JPWO2023151575 A5 JP WO2023151575A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diabetes
- pharmaceutical composition
- agent
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/075603 | 2022-02-09 | ||
| CN2022075603 | 2022-02-09 | ||
| PCT/CN2023/074938 WO2023151575A1 (en) | 2022-02-09 | 2023-02-08 | Heterocyclic glp-1 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025506474A JP2025506474A (ja) | 2025-03-11 |
| JPWO2023151575A5 true JPWO2023151575A5 (https=) | 2026-02-17 |
| JP2025506474A5 JP2025506474A5 (https=) | 2026-02-17 |
Family
ID=87563628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547308A Pending JP2025506474A (ja) | 2022-02-09 | 2023-02-08 | ヘテロ環ｇｌｐ－１アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250145596A1 (https=) |
| EP (1) | EP4476213A1 (https=) |
| JP (1) | JP2025506474A (https=) |
| CN (1) | CN119072474A (https=) |
| WO (1) | WO2023151575A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN119343343A (zh) * | 2022-02-09 | 2025-01-21 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3555064B9 (en) * | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| PE20231181A1 (es) * | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
-
2023
- 2023-02-08 WO PCT/CN2023/074938 patent/WO2023151575A1/en not_active Ceased
- 2023-02-08 CN CN202380032342.9A patent/CN119072474A/zh active Pending
- 2023-02-08 JP JP2024547308A patent/JP2025506474A/ja active Pending
- 2023-02-08 US US18/837,146 patent/US20250145596A1/en active Pending
- 2023-02-08 EP EP23752355.0A patent/EP4476213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021219019A5 (https=) | ||
| JPWO2021160127A5 (https=) | ||
| JP2021091683A5 (https=) | ||
| JPWO2023151575A5 (https=) | ||
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JPWO2021155841A5 (https=) | ||
| JPWO2022028572A5 (https=) | ||
| KR20070004078A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| TWI864650B (zh) | Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物 | |
| JP2008525477A (ja) | Ｇｌｐ−１アゴニスト、組成物、方法および使用 | |
| JPWO2022078380A5 (https=) | ||
| US20110071159A1 (en) | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament | |
| JPWO2023198140A5 (https=) | ||
| US20250042856A1 (en) | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 | |
| CA3133768A1 (en) | Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia | |
| TW201105336A (en) | Combined medicine of pyrazole derivative and biguanide drug | |
| US8349862B2 (en) | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | |
| JP2022525948A (ja) | 高血糖症の治療に有用なヘテロアリール（ヘテロシクリル）メタノール化合物 | |
| TW201904968A (zh) | 以三唑并吡啶治療rbp4相關疾病之方法 | |
| JPWO2023151574A5 (https=) | ||
| JPWO2023138684A5 (https=) | ||
| RU2670197C1 (ru) | Соединение, обладающее агонистической активностью в отношении GPR119, способ его получения и фармацевтическая композиция, содержащая его в качестве эффективного компонента | |
| CN116444482B (zh) | 噻吩-2-羧酸衍生物、其制备方法及医药用途 | |
| WO2024061310A1 (zh) | 一种glp-1和gip双受体激动剂药物组合物及其用途 | |
| JP5252585B2 (ja) | 代謝障害の治療のための化合物 |